The cost of prescription weight loss drugs has risen by an average of 4.5% at the start of 2024, as per a recent analysis for the Wall Street Journal. This report comes in the wake of increasing demand for these drugs both in Northeast Ohio and across the nation. Prices of semaglutides, widely recognized treatments for diabetes and weight management in overweight patients, have also seen an upsurge. Notably, the cost of Novo Nordisk’s Ozempic is now 3.5% higher at $970 for a month’s supply, while Eli Lilly’s Mounjaro has increased by 4.5%, now setting customers back $1,070 a month.
Higher costs coupled with surging demand are causing a strain on the availability of semaglutide drugs. Obesity medicine specialist, Dr. Reena Bose from the Cleveland Clinic, revealed that some of her patients have been waiting for months to receive these drugs. A delay has been reported particularly for Wegovy, a semaglutide sanctioned for weight loss treatment in 2021, with its listed price being roughly $1,350. Nonetheless, manufacturer Novo Nordisk asserts that 80% of insured patients on Wegovy are paying under $25 a month.
Market circumstances and inflation are considered in setting drug prices as per Novo Nordisk, while Eli Lilly bases theirs on value, efficacy, and safety. Additional price hikes are expected from other pharmaceutical companies in the coming weeks. Surprisingly, a survey conducted in October last year revealed that only 25% of employers offered coverage for GLP-1 medications, used for managing diabetes and obesity, while 21% were unaware of their existence. Also, 38% of respondents perceived the high costs of GLP-1s as a potential barrier to offering coverage.
Despite the challenges, Dr. Bose is optimistic that more companies entering the market will lead to more competitive pricing. Increased competition could also mean these drugs become instantly available to patients, provided manufacturers can keep up with production.
However, the limited supply and exorbitant prices of weight loss drugs have given rise to counterfeit versions. The Food and Drug Administration issued a warning after thousands of phony Ozempic were confiscated in December. Advice to consumers is to obtain their prescriptions from a certified provider and state-licensed pharmacies and to have a licensed physician manage their weight loss journey to make any necessary adjustments.
Above all, Dr. Bose stressed that semaglutide drugs are not a universal remedy for obesity. According to her, effective weight loss must be personally tailored and involves adhering to a healthy lifestyle. She concluded her remarks by expressing optimism that better strategies from insurance companies and regulators could improve access to these drugs and reduce prices.
